Literature DB >> 22947694

Central dopaminergic activity influences metabolic parameters in healthy men.

Ludmila Brunerova1, Jana Potockova, Jiri Horacek, Jiri Suchy, Michal Andel.   

Abstract

BACKGROUND/AIMS: Central dopaminergic activity is probably linked to regulation of glucose and lipid metabolism and weight maintenance. The aim of our study was to evaluate the relationship between central dopaminergic activity measured using the apomorphine challenge test and metabolic parameters in healthy men.
METHODS: Forty-two healthy men (average age 43.5 ± 7.4 years, body mass index, BMI, 27.4 ± 5.7) were examined anthropometrically and biochemically (glycemia, lipids, glycated hemoglobin). Central dopaminergic activity was assessed as the area under the curve (AUC) of prolactin (PRL) and growth hormone (GH) responses to the apomorphine challenge test after sublingual administration of apomorphine in a dose of 0.033 mg/kg. Insulin resistance was quantified by calculation of glucose disposal and metabolic clearance rate during a euglycemic hyperinsulinemic clamp on two insulin levels (1 and 10 mIU/kg/min). Linear regression was used for statistical analysis.
RESULTS: Hormonal responses correlated negatively with age (for AUC/GH r = -0.33; p = 0.031) and BMI (AUC/GH r = -0.41; p = 0.007). After adjustment for age and BMI, a statistically significant negative correlations between AUC/PRL and total cholesterol (r = -0.41; p = 0.007), AUC/GH and HbA1c (r = -0.37; p = 0.016) and AUC/GH and HOMA (homeostasis model assessment; r = -0.345; p = 0.025) were observed.
CONCLUSION: Central dopaminergic activity declines with age and BMI. Higher total cholesterol, glycated hemoglobin and insulin resistance parameters are connected with lower central dopamine tone.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22947694     DOI: 10.1159/000338405

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  6 in total

1.  COMT Val158Met Polymorphism, Cardiometabolic Risk, and Nadir CD4 Synergistically Increase Risk of Neurocognitive Impairment in Men Living With HIV.

Authors:  Rowan Saloner; Maria J Marquine; Erin E Sundermann; Suzi Hong; John Allen McCutchan; Ronald J Ellis; Robert K Heaton; Igor Grant; Mariana Cherner
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

Review 2.  Schizophrenia: a disorder of broken brain bioenergetics.

Authors:  Nicholas D Henkel; Xiajoun Wu; Sinead M O'Donovan; Emily A Devine; Jessica M Jiron; Laura M Rowland; Zoltan Sarnyai; Amy J Ramsey; Zhexing Wen; Margaret K Hahn; Robert E McCullumsmith
Journal:  Mol Psychiatry       Date:  2022-03-09       Impact factor: 13.437

3.  Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System.

Authors:  Petr Winkler; Jiří Horáček; Aneta Weissová; Martin Šustr; Martin Brunovský
Journal:  Int J Environ Res Public Health       Date:  2015-12-10       Impact factor: 3.390

Review 4.  The role of hypothalamic endoplasmic reticulum stress in schizophrenia and antipsychotic-induced weight gain: A narrative review.

Authors:  Ruqin Zhou; Meng He; Jun Fan; Ruoxi Li; Yufeng Zuo; Benben Li; Guanbin Gao; Taolei Sun
Journal:  Front Neurosci       Date:  2022-09-16       Impact factor: 5.152

Review 5.  Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson's Disease.

Authors:  Juhyun Song; Jongpil Kim
Journal:  Front Aging Neurosci       Date:  2016-03-30       Impact factor: 5.750

Review 6.  Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease-Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors.

Authors:  Kai-Jung Lin; Tzu-Jou Wang; Shang-Der Chen; Kai-Lieh Lin; Chia-Wei Liou; Min-Yu Lan; Yao-Chung Chuang; Jiin-Haur Chuang; Pei-Wen Wang; Jong-Jer Lee; Feng-Sheng Wang; Hung-Yu Lin; Tsu-Kung Lin
Journal:  Antioxidants (Basel)       Date:  2021-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.